GlassScriptPhysician profile
Hung H Nguyen
NPI 1619921095
$10,152.30
in general payments reported to CMS, 2019-2025
32 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,419 · 2020: $527 · 2021: $1,712 · 2022: $1,531 · 2023: $1,663 · 2024: $2,249 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,834 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125 · Travel and Lodging: $5.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,833.81 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $124.88 |
| Travel and Lodging | $5.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,588.85 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,472.65 | 2019-2025 | Otezla, Evenity, Repatha |
| Janssen Pharmaceuticals, INC | $873.40 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $759.98 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $314.28 | 2019-2025 | Capvaxive, Verquvo, Januvia |
| Lilly USA, LLC | $296.01 | 2023-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $253.73 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $169.76 | 2021-2024 | |
| Gilead Sciences, INC. | $163.56 | 2019 | |
| Sumitomo Pharma America, INC. | $153.26 | 2024 | Gemtesa, Myfembree |
| Mylan Specialty L.P. | $147.23 | 2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $141.80 | 2019 | |
| Phathom Pharmaceuticals, INC. | $123.49 | 2024 | Voquezna |
| Amarin Pharma, INC. | $116.90 | 2020-2022 | |
| Astellas Pharma US INC | $111.24 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $79.22 | 2021 | |
| Genentech USA, INC. | $59.98 | 2020-2022 | |
| Dexcom, INC. | $54.06 | 2021-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $38.84 | 2020-2025 | Nexletol |
| Glaxosmithkline, LLC. | $38.07 | 2021-2023 | Shingrix |
| Abbvie INC. | $32.91 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $21.93 | 2019 | |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Pfizer INC. | $17.44 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.23 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.18 | 2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $13.99 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.00 | 2022 | |
| Radius Health, INC. | $12.92 | 2021 | |
| Abbott Laboratories | $12.82 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $12.48 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hung Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.